Colleen's Dream Foundation funds ovarian cancer clinical trial

SCOTTSDALE, ARIZ. — April 3, 2018 — Colleen’s Dream Foundation, a Scottsdale-based nonprofit dedicated to supporting ovarian cancer research, recently awarded Translational Genomics Research Institute (TGen) $450,000 to fund a clinical trial for a newly developed ovarian cancer drug treatment.

Colleen’s Dream celebrated its fifth annual fundraising event, the Evening of Dreams Gala in late February. This year’s gala was record-breaking for the foundation, with more than 650 attendees and $200,000 raised from the live auction and paddle raise portion of the evening alone. Combined with prior Colleen’s Dream donations to TGen, this support will fully enable the clinical trial.

“The research being done at TGen is some of the most exciting we’ve ever seen,” said Nicole Cundiff, CEO of Colleen’s Dream Foundation. “Whether the drug they developed leads to another amazing discovery, or it becomes a first line ovarian cancer treatment, we truly believe what they’re doing will move the needle and we couldn’t be more proud to support an institute located here in Arizona.”

TGen, based in Phoenix, alongside an international team of collaborators, discovered a mutation in a gene known as SMARCA4, which drives a specific type of extremely aggressive ovarian cancer known as Small Cell


Article originally posted at

Click here for the full story


Privacy Policy / Terms Of Use

       Powered by MMD